No Data
Chongqing Taiji Unit's Atropine Sulfate Injection Passes Regulatory Evaluation
Sinolink: Pharmaceutical sector under pressure in the early stage, reversal in 2025 comes from three major opportunities.
With the continuous aging of the population, stable expansion of residents' medical consumption, and the continuous recovery of industry diagnosis and treatment volume, the long-term growth logic of the medical industry remains clear, and the overall foundation is stable.
Chongqing Taiji Industry (600129.SH): Atropine sulfate injection has passed the consistency evaluation for generic drugs.
On November 26, Glodon Holdings reported that chongqing taiji industry (600129.SH) announced that its holding subsidiary, Southwest Pharmaceutical Co., Ltd. (referred to as: Southwest Pharmaceutical), received the "Pharmaceutical Supplement Application Approval Notice" from the National Medical Products Administration for atropine sulfate injection (Specification: 1ml:0.5mg). Southwest Pharmaceutical's atropine sulfate injection has passed the consistency evaluation of generic drug quality and efficacy. This product is mainly used for various visceral cramps, such as gastrointestinal colic and bladder irritation symptoms; premedication before general anesthesia, severe nocturnal sweating, and drooling; and sinus node block, atrioventricular block, and other slow heart rhythms caused by excessive vagus nerve excitement.
Chongqing Taiji Industry (600129.SH): The company is actively promoting the industrialization of cordyceps.
On November 25, Gelonghui reported that chongqing taiji industry (600129.SH) stated on its investor interaction platform that Taiji Shangcao is the company's ecological nurturing brand for Cordyceps. The official flagship store of Taiji Shangcao serves as the online sales platform. The company is actively promoting the industrialization of Cordyceps while optimizing the sales channels for Cordyceps, and relevant information will be announced by the company.
Fewer Investors Than Expected Jumping On Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129)
Chongqing Taiji Industry (600129.SH): Exploring the efficacy of pharmaceuticals and analyzing the mechanism of action of traditional Chinese medicine with multiple targets, components, and pathways through a large AI model of traditional Chinese medicine.
Gelonghui reported on November 22 that chongqing taiji industry (600129.SH) stated on the investor interaction platform that the company is exploring the efficacy of pharmaceuticals and analyzing the mechanisms of action of traditional chinese medicine through its AI large model.
Chongqing Taiji Industry(Group) Co.,Ltd (SHSE:600129) Looks Inexpensive But Perhaps Not Attractive Enough
